Anemia

The U.S. Food and Drug Administration ( FDA ) has approved Tafinlar ( Dabrafenib ) and ( Trametinib ), administered...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


Triple-negative breast cancer ( TNBC ) is an aggressive subtype of breast cancer, often resistant to standard of care therapies....


The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the...



The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and...


The FDA ( U.S. Food and Drug Administration ) has approved Lumoxiti ( Moxetumomab pasudotox-tdfk ) injection for intravenous use...


A study has evaluated the influence of anemia on long-term outcomes of patients with acute coronary syndrome undergoing percutaneous coronary...


Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ),...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...


The European Commission ( EC ) has approved Varuby ( oral Rolapitant tablets ) for the prevention of delayed nausea...


Neuroendocrine tumors ( NETs ) are a heterogeneous class of neoplasms with increasing incidence worldwide. Tumor behavior and patient survival...


Data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial investigating the use of Pembrolizumab ( Keytruda ),...



The FDA ( Food and Drug Administration ) has granted accelerated approval to Calquence ( Acalabrutinib ) for the treatment...


Immunotherapy in multiple myeloma is emerging as an effective modality in therapy of multiple myeloma with the approval of several...


Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival...


The FDA ( Food and Drug Administration ) has granted Priority Review for Atezolizumab ( anti-PD-L1; MPDL3280A ) for the...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...